2022
CAV2.3 expression is upregulated in the substantia nigra pars compacta of humans with Parkinson's disease
Sharifi P, Bae H, Gveric D, Gentleman S, Smith P, Tierney T, Alavian K. CAV2.3 expression is upregulated in the substantia nigra pars compacta of humans with Parkinson's disease. Brain Disorders 2022, 5: 100031. DOI: 10.1016/j.dscb.2022.100031.Peer-Reviewed Original Research
2021
Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker
Gaurav R, Yahia‐Cherif L, Pyatigorskaya N, Mangone G, Biondetti E, Valabrègue R, Ewenczyk C, Hutchison R, Cedarbaum J, Corvol J, Vidailhet M, Lehéricy S. Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker. Movement Disorders 2021, 36: 1592-1602. PMID: 33751655, PMCID: PMC8359265, DOI: 10.1002/mds.28531.Peer-Reviewed Original ResearchConceptsTotal intracranial volumePD patientsHealthy volunteersParkinson's diseaseIntracranial volumeObservational case-control studySubstantia nigra pars compactaDirect noninvasive assessmentDisease-modifying treatmentsEarly PD patientsFemale PD patientsTherapeutic drug trialsCase-control studyNeuromelanin-sensitive MRI techniquesNeuromelanin-sensitive imagingMale patientsFemale patientsPars compactaCohort IICohort IDrug trialsPatientsImaging biomarkersNoninvasive assessmentDisease severity
2020
KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease
Mao Q, Wang X, Chen B, Fan L, Wang S, Zhang Y, Lin X, Cao Y, Wu YC, Ji J, Xu J, Zheng J, Zhang H, Zheng C, Chen W, Cheng W, Luo X, Wang K, Zuo L, Kang L, Li CR, Luo X. KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease. Frontiers In Neuroscience 2020, 14: 651. PMID: 32655362, PMCID: PMC7324786, DOI: 10.3389/fnins.2020.00651.Peer-Reviewed Original ResearchPutamen gray matter volumesSubstantia nigra pars compactaGray matter volumeParkinson's diseaseMRNA expressionSingle nucleotide polymorphismsPD riskIndependent cohortMatter volumeDevelopment of PDPars compactaDopaminergic neuronsPutamenPutamen volumeSignificant associationPD associationsRisk allelesDiseaseSelective lossCohortGene variantsLoss of MINAR2 impairs motor function and causes Parkinson’s disease-like symptoms in mice
Ho R, Amraei R, De La Cena K, Sutherland E, Mortazavi F, Stein T, Chitalia V, Rahimi N. Loss of MINAR2 impairs motor function and causes Parkinson’s disease-like symptoms in mice. Brain Communications 2020, 2: fcaa047. PMID: 32954300, PMCID: PMC7425422, DOI: 10.1093/braincomms/fcaa047.Peer-Reviewed Original ResearchReceptor 2Parkinson's spectrum disordersDisease-like symptomsPars compactaΑ-synuclein protein expressionTyrosine hydroxylase-positive neuronsSubstantia nigra pars compactaFrontal lobe brainParkinson's disease-like symptomsLewy body dementiaImpairs motor functionSevere motor deficitsPrimary clinical symptomsReceptor 2 expressionKnockout mouse brainMotor control impairmentsSpectrum disorderCommon human neurodegenerative diseasesΑ-synuclein aggregationMotor deficitsClinical symptomsDopaminergic neuronsSpontaneous locomotorClinical hallmarkMotor function
2019
Post mortem examination of Parkinson's disease brains suggests decline in mitochondrial biomass, reversed by deep brain stimulation of subthalamic nucleus
Mallach A, Weinert M, Arthur J, Gveric D, Tierney TS, Alavian KN. Post mortem examination of Parkinson's disease brains suggests decline in mitochondrial biomass, reversed by deep brain stimulation of subthalamic nucleus. The FASEB Journal 2019, 33: 6957-6961. PMID: 30862197, DOI: 10.1096/fj.201802628r.Peer-Reviewed Original ResearchConceptsDeep brain stimulationParkinson's disease brainSubthalamic nucleusParkinson's diseaseDisease brainBrain stimulationPresynaptic terminalsSNpc neuronsEffects of DBSLong-term clinical benefitSubstantia nigra pars compactaLate-stage patientsMitochondrial biomassDA neuronsSTN-DBSSurgical treatmentNeuroprotective effectsPars compactaClinical benefitDA projectionsPD brainsDopaminergic neuronsDBS treatmentNeuromodulatory effectsPD cases
2017
Regulator of G‐protein signaling 6 (RGS6) expression in human substantia nigra pars compacta (SNc) and loss in Parkinson's disease (PD)
Luo Z, Ahlers K, Yang J, Chakravarti B, Stevens H, Narayanan N, Fisher R. Regulator of G‐protein signaling 6 (RGS6) expression in human substantia nigra pars compacta (SNc) and loss in Parkinson's disease (PD). The FASEB Journal 2017, 31 DOI: 10.1096/fasebj.31.1_supplement.659.23.Peer-Reviewed Original ResearchSubstantia nigra pars compactaSNc DA neuronsDA neuronsParkinson's diseasePD patientsHuman substantia nigra pars compactaPotential novel therapeutic targetCritical neuroprotective roleDA neuron degenerationTyrosine hydroxylase expressionNovel therapeutic targetDevastating neurodegenerative disorderAge-dependent lossSNc neuronsMotor deficitsNeuroprotective rolePars compactaPathogenic linkNeuron degenerationPD treatmentDopamine neuronsHydroxylase expressionBehavioral deficitsDA contentImmunohistochemical analysisThe Effects of Age, from Young to Middle Adulthood, and Gender on Resting State Functional Connectivity of the Dopaminergic Midbrain
Peterson AC, Zhang S, Hu S, Chao HH, Li CR. The Effects of Age, from Young to Middle Adulthood, and Gender on Resting State Functional Connectivity of the Dopaminergic Midbrain. Frontiers In Human Neuroscience 2017, 11: 52. PMID: 28223929, PMCID: PMC5293810, DOI: 10.3389/fnhum.2017.00052.Peer-Reviewed Original ResearchSubstantia nigra pars compactaVentral tegmental areaAttention-deficit/ hyperactivity disorderState functional connectivityAge-related changesEffect of ageFunctional connectivityParahippocampal gyrusParkinson's diseaseMiddle adulthoodDopaminergic ventral tegmental areaBilateral angular gyrusOrbital frontal regionsBlood oxygenation level-dependent (BOLD) signalLevel-dependent signalPosterior orbital gyrusTime courseNeural basisDopaminergic midbrainHyperactivity disorderNeural mechanismsAngular gyrusPars compactaFrontal regionsDopaminergic structuresNeuroprotective potential of quercetin in combination with piperine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity
Singh S, Jamwal S, Kumar P. Neuroprotective potential of quercetin in combination with piperine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Neural Regeneration Research 2017, 12: 1137-1144. PMID: 28852397, PMCID: PMC5558494, DOI: 10.4103/1673-5374.211194.Peer-Reviewed Original ResearchSubstantia nigra pars compactaAnti-inflammatory propertiesPars compactaNeuroprotective potentialTetrahydropyridine-induced neurotoxicityInjection of MPTPStrong neuroprotective effectSignificant motor deficitsBioavailability of antioxidantsOpen field testOxidative stress parametersLow oral bioavailabilityNeuroinflammatory cytokinesMotor deficitsNeuroprotective effectsRotarod performanceCombination therapyDopaminergic neuronsGrip strengthInflammatory responseBilateral infusionsBehavioral abnormalitiesDay 1MPTPStereotaxic apparatus
2015
Resting-State Functional Connectivity of the Locus Coeruleus in Humans: In Comparison with the Ventral Tegmental Area/Substantia Nigra Pars Compacta and the Effects of Age
Zhang S, Hu S, Chao HH, Li CR. Resting-State Functional Connectivity of the Locus Coeruleus in Humans: In Comparison with the Ventral Tegmental Area/Substantia Nigra Pars Compacta and the Effects of Age. Cerebral Cortex 2015, 26: 3413-3427. PMID: 26223261, PMCID: PMC4961017, DOI: 10.1093/cercor/bhv172.Peer-Reviewed Original ResearchConceptsVentral tegmental area/substantia nigra pars compactaSubstantia nigra pars compactaLocus coeruleusPars compactaFunctional connectivityResting-state functional connectivityCerebral functional connectivityNumerous animal studiesFronto-parietal cortexRight anterior insulaResting-state fMRI dataEffect of ageCerebral cortexNoradrenergic inputCognitive motor controlAnimal studiesCortex decreasesHealthy adultsCerebellum increasesMidbrain nucleiBilateral amygdalaMidbrain structuresAnterior insulaCognitive manifestationsMotor control
2014
Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats
Suzuki S, Kawamata J, Iwahara N, Matsumura A, Hisahara S, Matsushita T, Sasaki M, Honmou O, Shimohama S. Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats. Neuroscience Letters 2014, 584: 276-281. PMID: 25449872, DOI: 10.1016/j.neulet.2014.10.039.Peer-Reviewed Original ResearchConceptsHuman bone marrow-derived mesenchymal stem cellsTherapeutic effectParkinson's diseaseCalcium binding adaptor molecule 1Mesenchymal stem cell administrationSubstantia nigra pars compactaHemi-parkinsonian rat modelParkinsonian model ratsTH-positive neuronsAdaptor molecule 1Anti-inflammatory factorsStem cell administrationNovel therapeutic optionsSham-operated ratsBone marrow-derived mesenchymal stem cellsMarrow-derived mesenchymal stem cellsGlial activationPars compactaCell administrationTherapeutic optionsDopaminergic neuronsModel ratsDopaminergic neurodegenerationNovel therapiesRat modelThe lifelong maintenance of mesencephalic dopaminergic neurons by Nurr1 and engrailed
Alavian KN, Jeddi S, Naghipour SI, Nabili P, Licznerski P, Tierney TS. The lifelong maintenance of mesencephalic dopaminergic neurons by Nurr1 and engrailed. Journal Of Biomedical Science 2014, 21: 27. PMID: 24685177, PMCID: PMC3998737, DOI: 10.1186/1423-0127-21-27.Peer-Reviewed Original ResearchConceptsMesencephalic dopaminergic neuronsDopaminergic neuronsParkinson's diseaseSubstantia nigra pars compactaMidbrain dopaminergic neuronsLong-term survivalPars compactaSet of neuronsPathological hallmarkNormal physiological functionNeurotransmitter identityNeurophysiological functionsNeuronsDiseaseLifelong maintenanceCurrent reviewTranscription factorsNurr1DegenerationPhysiological functionsReviewFactorsSpecific vulnerabilitiesMidbrainCompacta
2010
Focal cortical and subcortical atrophy in early Parkinson's disease
Tinaz S, Courtney MG, Stern CE. Focal cortical and subcortical atrophy in early Parkinson's disease. Movement Disorders 2010, 26: 436-441. PMID: 21462259, PMCID: PMC4502575, DOI: 10.1002/mds.23453.Peer-Reviewed Original ResearchConceptsParkinson's disease patientsDisease patientsParkinson's diseaseDisease groupEarly-stage Parkinson's disease patientsSubstantia nigra pars compactaAnxiety state scoresFocal cortical thinningEarly Parkinson's diseaseParkinson's disease groupCortical thickness changesManifest Parkinson's diseaseStriatal volume lossSubcortical structural changesOccipito-parietal areasHealthy control participantsLimbic cortexPars compactaSubcortical atrophyCortical thinningVentrolateral prefrontal cortexCortical thicknessSubcortical volumesControl groupAlzheimer's disease
2009
Ghrelin Promotes and Protects Nigrostriatal Dopamine Function via a UCP2-Dependent Mitochondrial Mechanism
Andrews ZB, Erion D, Beiler R, Liu ZW, Abizaid A, Zigman J, Elsworth JD, Savitt JM, DiMarchi R, Tschöp M, Roth RH, Gao XB, Horvath TL. Ghrelin Promotes and Protects Nigrostriatal Dopamine Function via a UCP2-Dependent Mitochondrial Mechanism. Journal Of Neuroscience 2009, 29: 14057-14065. PMID: 19906954, PMCID: PMC2845822, DOI: 10.1523/jneurosci.3890-09.2009.Peer-Reviewed Original ResearchConceptsDA cell lossNigrostriatal dopamine functionParkinson's diseaseDopamine functionCell lossSubstantia nigra pars compactaSNpc DA neuronsStriatal dopamine levelsStriatal dopamine lossExogenous ghrelin administrationLoss of appetiteDopamine cell degenerationNovel therapeutic strategiesMitochondrial mechanismsTyrosine hydroxylase mRNAReactive oxygen species productionMPTP treatmentPeripheral ghrelinSNpc cellsTetrahydropyridine (MPTP) treatmentDA neuronsDopamine lossGhrelin administrationPars compactaCatecholaminergic neurons
2007
Motor deficits and altered striatal gene expression in aphakia (ak) mice
Singh B, Wilson JH, Vasavada HH, Guo Z, Allore HG, Zeiss CJ. Motor deficits and altered striatal gene expression in aphakia (ak) mice. Brain Research 2007, 1185: 283-292. PMID: 17949697, PMCID: PMC3904435, DOI: 10.1016/j.brainres.2007.09.006.Peer-Reviewed Original ResearchConceptsSubstantia nigra pars compactaMonths of lifeAK miceWT miceParkinson's diseaseMotor performanceStriatal gene expressionDopaminergic denervationNigrostriatal dysfunctionStriatal denervationMotor deficitsPars compactaMotor abnormalitiesAphakia miceMice progressMotor functionStriatal transcriptomeDRD2 expressionPole testWT controlsSemi-quantitative RT-PCRAge groupsMiceRT-PCRTime points
2006
Uncoupling protein‐2 promotes nigrostriatal dopamine neuronal function
Andrews ZB, Rivera A, Elsworth JD, Roth RH, Agnati L, Gago B, Abizaid A, Schwartz M, Fuxe K, Horvath TL. Uncoupling protein‐2 promotes nigrostriatal dopamine neuronal function. European Journal Of Neuroscience 2006, 24: 32-36. PMID: 16882005, DOI: 10.1111/j.1460-9568.2006.04906.x.Peer-Reviewed Original ResearchMeSH Keywords3,4-Dihydroxyphenylacetic AcidAnimalsCorpus StriatumDopamineDopamine Plasma Membrane Transport ProteinsImmunohistochemistryIon ChannelsMaleMembrane Transport ProteinsMiceMice, KnockoutMitochondrial ProteinsMotor ActivityNeuronsSubstantia NigraTyrosine 3-MonooxygenaseUncoupling Protein 2ConceptsSubstantia nigra pars compactaDopamine neuronal functionUCP2-KO miceParkinson's diseaseNeuronal functionNigrostriatal dopamine functionTyrosine hydroxylase immunoreactivityUCP2 knockout miceDopamine transporter immunoreactivityProtein 2Wild-type controlsHydroxylase immunoreactivityPars compactaDopamine turnoverTransporter immunoreactivityDopamine ratioBehavioral deficitsLocomotor functionNucleus accumbensBiochemical deficitsDopamine functionBrain regionsNeurological pathologiesDiseaseMice
1994
Synaptic connections between pars compacta and pars reticulata neurones: electrophysiological evidence for functional modules within the substantia nigra
Hajós M, Greenfield S. Synaptic connections between pars compacta and pars reticulata neurones: electrophysiological evidence for functional modules within the substantia nigra. Brain Research 1994, 660: 216-224. PMID: 7820690, DOI: 10.1016/0006-8993(94)91292-0.Peer-Reviewed Original ResearchConceptsInhibitory postsynaptic potentialsSubstantia nigraReticulata neuronesPars compactaPostsynaptic potentialsPars reticulataApical dendritesPostsynaptic responsesIntracellular recordingsDopaminergic neuronesIntracellular stainingExtrinsic inhibitionElectrical stimulationSynaptic connectionsLocal circuitsReticulata cellsStimulating electrodesNeuronesNigraCompactaElectrophysiological evidenceStimulationTopographic patternsInhibitionMost inhibition
1992
Differential actions of acetylcholinesterase on the soma and dendrites of dopaminergic substantia nigra neurons in vitro
Hajós M, Greenfield S. Differential actions of acetylcholinesterase on the soma and dendrites of dopaminergic substantia nigra neurons in vitro. Brain Research 1992, 585: 416-420. PMID: 1511329, DOI: 10.1016/0006-8993(92)91248-d.Peer-Reviewed Original ResearchConceptsPars reticulataApical dendritesDopaminergic neuronsDopaminergic substantia nigra neuronsSubstantia nigra neuronsSubset of neuronsNon-cholinergic actionsAction of AChEPars compactaSubstantia nigraCalcium conductanceNeuronsPotassium channelsSodium channelsDifferential actionIonic basisDendritesAChEHyperpolarizationReticulataCompactaNigraActionSoma
1989
The effect of acute and chronic treatment with SCH 23390 on the spontaneous activity of midbrain dopamine neurons
Esposito E, Bunney B. The effect of acute and chronic treatment with SCH 23390 on the spontaneous activity of midbrain dopamine neurons. European Journal Of Pharmacology 1989, 162: 109-113. PMID: 2656273, DOI: 10.1016/0014-2999(89)90609-2.Peer-Reviewed Original ResearchConceptsSubstantia nigra pars compactaVentral tegmental areaActive DA neuronsSCH 23390Chronic treatmentDA neuronsDopamine neuronsDepolarization blockSpontaneous activityDA receptor blockadeAcute subcutaneous injectionGroups of ratsMidbrain dopamine neuronsChronic haloperidolReceptor blockadeChronic administrationPars compactaTegmental areaAntipsychotic drugsSubcutaneous injectionChronic experimentsMarked reductionNeuronsTreatmentHaloperidol
1985
Differential visualization of dopamine and norepinephrine uptake sites in rat brain using [3H]mazindol autoradiography
Javitch JA, Strittmatter SM, Snyder SH. Differential visualization of dopamine and norepinephrine uptake sites in rat brain using [3H]mazindol autoradiography. Journal Of Neuroscience 1985, 5: 1513-1521. PMID: 4009243, PMCID: PMC6565258, DOI: 10.1523/jneurosci.05-06-01513.1985.Peer-Reviewed Original ResearchConceptsDA uptake sitesNE uptake sitesUptake sitesRat brainSubstantia nigra pars compactaAnterior olfactory nucleusVentral tegmental areaIbotenic acid lesionsAnteroventral thalamusNoradrenergic terminalsOlfactory nucleusSolitary tractMazindol bindingPars compactaSomatodendritic regionOlfactory tubercleDopaminergic axonsLocus coeruleusNorepinephrine uptakeTegmental areaPeriventricular nucleusSubthalamic nucleusIbotenic acidStria terminalisAcid lesions
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply